Editorial: Malaria vaccine: Why is it taking so long?

Expert Review of Vaccines

Volumn 9, Issue 2, 2010, Pages 111-114

  Corradin, Giampietro ^a   Kajava, Andrey V ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; MALARIA VACCINE; PESTICIDE;

BED NET; DEVELOPMENT; EDITORIAL; ENVIRONMENTAL MANAGEMENT; ERADICATION THERAPY; HUMAN; MALARIA; MORTALITY; NONHUMAN; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; HISTORY; IMMUNOLOGY; MEDICAL RESEARCH;

BIOMEDICAL RESEARCH; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MALARIA; MALARIA VACCINES;

EID: 77950351452     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.154     Document Type: Editorial

References (23)

1. Snowden F. The Conquest of Malaria: Italy, 1900-1962. Yale University Press, CT, USA (2006).
2. Herrington DA, Clyde DF, Losansky G et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328, 257-259 (1987).
3. Ballou WR, Hoffman SL, Sherwood JA et al. Safety and effcacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1, 1277-1281 (1987).
4. Valero MV, Amador LR, Galindo C et al. Vaccination with Spf 66 a chemically synthesized vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 341, 705-710 (1993).
5. Alonso PL, Smith T, Armstrong Schellenberg JQM et al. Randomised trial of effcacy of Spf 66 vaccine against Plasmodium falciparum malaria in children in South Tanzania. Lancet 344, 1175-1181 (1994).
6. Stoute JA, Slaoui M, Heppner D et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J Med. 336, 86-91 (1997).
7. Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366, 2012-2018 (2005).
8. Aponte JJ, Aide P, Renom M et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled Phase I/IIb trial. Lancet 370, 1543-1551 (2007).
9. Sherman IW. The Elusive Malaria Vaccine: Miracle or Mirage. ASM Press, Washington, DC, USA (2009).
10. Gardner MJ, Hall N, Fung E, White O et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 498-511 (2002).
11. Aguiar JC, LaBaer J, Blair PL. High-throughput generation of P. falciparum functional molecules by recombinational cloning. Genome Res. 14, 2076-2082 (2004).
12. Mehlin C, Boni E, Buckner FS. Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol. Biochem. Parasitol. 148, 144-160 (2006).
13. Tsuboi T, Takeo S, Iriko H et al. Wheat germ cell-free system-based production of malaria proteins for discovery of novel vaccine candidates. Infect. Immun. 76, 1702-1708 (2008).
14. Corradin G, Villard V, Kajava AV. Protein structure based strategies for antigen discovery and vaccine development against malaria and other pathogens. Endocr. Metab. Immune Disord. Drug. Targets 7, 259-265 (2007).
15. Villard V, Agak GW, Frank G et al. Rapid identifcation of malaria vaccine candidates based on a-helical coiled coil protein motif. PLoS One 2, e645 (2007).
16. Barlow Barlow DJ, Edwards MS, Thornton JM. Continuous and discontinuous protein antigenic determinants. Nature 322, 747-748 (1986).
17. Martin L, Vita C. Engineering novel bioactive mini-proteins from small size natural and de novo designed scaffolds. Curr. Protein Pept. Sci. 1, 403-430 (2000).
18. Lu SM, Hodges RS. A de novo designed template for generating conformation-specifc antibodies that recognize a-helices in proteins. J. Biol. Chem. 277, 23515-23524 (2002).
19. Harbury PB, Zhang T, Kim PS, Alber T. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262, 1401-1407 (1993).
20. Wright PE, Dyson HJ. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J. Mol. Biol. 293, 321-331 (1999).
21. Feng ZP, X. Zhang X, Han P, Arora N, Anders RF, Norton RS. Abundance of intrinsically unstructured proteins in P. falciparum and other apicomplexan parasite proteomes. Mol. Biochem. Parasitol. 150, 256-267 (2006).
22. Olugbile S, Kulangara C, Bang G et al. Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage associated P. falciparum protein PFF0165c. Infect. Immun. 7 7, 5701-5709 (2009).
23. Kulangara, C, Kajava AV. Corradin G, Felger I. Sequence conservation in Plasmodium falciparum a-helical coiled coil domains proposed for vaccine development. PLoS One 4, e5419 (2009).